Article info
PDFA difficult case
Anti-HMGCR myopathy: barriers to prompt recognition
- Correspondence to Dr Enrico Bugiardini, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, London, UK; e.bugiardini{at}ucl.ac.uk
Citation
Anti-HMGCR myopathy: barriers to prompt recognition
Publication history
- Accepted November 9, 2022
- First published December 23, 2022.
Online issue publication
May 25, 2023
Article Versions
- Previous version (25 May 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Muscle disease
- Making sense of the clinical spectrum of limb girdle muscular dystrophies
- Autoantibody testing in idiopathic inflammatory myopathies
- Diagnosis and management of the limb girdle muscular dystrophies
- Muscle biopsy: what and why and when?
- Muscle diseases: mimics and chameleons
- Myopathy with antibodies to the signal recognition particle: clinical and pathological features
- A ‘limb-girdle muscular dystrophy’ responsive to asthma therapy
- Diagnosis and new treatments in muscular dystrophies
- Proximal myopathy: diagnostic approach and initial management